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The pro-peptide of transforming growth factor a (proTGFa) was recently found in hepatocyte nuclei preparing for DNA replication,
which suggests a role of nuclear proTGFa for mitogenic signalling. This study investigates whether the nuclear occurrence of the pro-
peptide is involved in the altered growth regulation of (pre)malignant hepatocytes. In human hepatocarcinogenesis, the incidence of
proTGFa-positive and replicating nuclei gradually increased from normal liver, to dysplastic nodules, to hepatocellular carcinoma.
ProTGFa-positive nuclei almost always were in DNA synthesis. Also, in rat hepatocarcinogenesis, proTGFa-positive nuclei occurred in
(pre)malignant hepatocytes at significantly higher incidences than in unaltered hepatocytes. For functional studies unaltered (GSTp
 )
and premalignant (GSTp
þ) rat hepatocytes were isolated by collagenase perfusion and cultivated. Again, DNA synthesis occurred
almost exclusively in proTGFa-positive nuclei. GSTp
þ hepatocytes showed an B3-fold higher frequency of proTGFa-positive nuclei
and DNA replication than GSTp
  cells. Treatment of cultures with the mitogen cyproterone acetate (CPA) elevated the incidence of
proTGFa-positive nuclei and DNA synthesis in parallel. Conversely, transforming growth factor b1 (TGFb1) lowered both. These
effects of CPA and TGFb1 were significantly more pronounced in GSTp
þ than in GSTp
  hepatocytes. In conclusion, nuclear
translocation of proTGFa increases in the course of hepatocarcinogenesis and appears to be involved in the inherent growth
advantage of (pre)malignant hepatocytes.
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Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide, particularly in Asia and Africa, accounting for
about 1 million deaths per year (Parkin et al, 2001). Recently, its
incidence has substantially increased in Europe and the United
States (El-Serag and Mason, 1999; Parkin et al, 2001). Transform-
ing growth factor a (TGFa) is one of the cytokines, causally
involved in the pathogenesis of liver cancer (Kiss et al, 1997;
Grisham, 2001). It is produced by hepatocytes and nonparench-
ymal liver cells for paracrine, autocrine and/or juxtacrine
stimulation, as shown in developing, regenerating, preneoplastic
and neoplastic livers of rodents and humans (Mead and Fausto,
1989; Miller et al, 1995; Grisham, 1997; Kiss et al, 1997; Yarden and
Sliwkowski, 2001). Transforming growth factor a appears to be
upregulated in all stages of liver cancer development. Single
hepatocytes, infected with the hepatitis-B virus, overexpress TGFa
due to transactivation of the TGFa gene by the virus (Schirmacher
et al, 1996). Hepatocellular adenomas and carcinomas as well as
childhood hepatoblastomas have been found to be rich in TGFa,
leading to elevated plasma levels of this cytokine (Yamaguchi et al,
1995; Kiss et al, 1997; Grisham, 2001).
According to textbook knowledge, TGFa is produced as a
precursor transmembrane molecule (proTGFa). The ectodomain of
the pro-peptide may be shed from the cell surface, where it may
bind to and activate the erbb-1 receptor, that confers the growth
signal via phosphorylation cascades to the nucleus (Massague ´,
1990; Yarden and Sliwkowski, 2001). Considering the upregulation
of TGFa in human malignancies, including liver cancer, hope
focuses on the possible therapeutic benefit of blocking TGFa-
evoked signal transduction on the cell surface, for example, by
blockade of the receptor or of ligand–receptor interactions
(Levitzki and Gazit, 1995; Mendelsohn, 1997). In a recent study,
however, we have shown that hepatocytes in the intact liver and in
primary culture synthesise proTGFa that translocates to the
nucleus, where it appears to be involved in the mitogenic response
of the cell (Grasl-Kraupp et al, 2002). This proposed novel pathway
was induced by various different growth stimuli and is active in
three different mammalian species, including humans. In mouse
hepatocytes, almost all of the proTGFa-pos nuclei were also
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spositive for erbb-1 (Schausberger et al, 2003). Moreover, several
very recent papers suggest that the erbb receptors 1, 3 and 4 may
bypass the protein phosphorylation cascades for transducing
mitogenic stimuli (Lin et al, 2001; Ni et al, 2001; Offterdinger et al,
2002). Thus, there is considerable evidence of a direct action of
growth factors/growth factor receptors from the EGF/erbb-
receptor family in the nucleus (Wells and Marti, 2002). The
question emerges whether the nuclear occurrence of proTGFa is
involved in the altered growth regulation of (pre)malignant cells.
Rodent liver provides excellent tools for functional studies on
hepatocarcinogenesis (Pitot, 1990; Grasl-Kraupp et al, 1997;
Grisham, 1997). Treatment of rats with genotoxic carcinogens,
such as N-nitrosomorpholine (NNM), induces single initiated
hepatocytes that are detectable by their selective immunoreactivity
for placental glutathione-S-transferase (GSTp
þ cells); a consider-
able fraction of these cells develops to GSTp
þ (pre)malignancy
(Grasl-Kraupp et al, 2000). Although human HCC often do not
express GSTp due to epigenetic silencing of the gene, GSTp
þ
lesions of rats and (pre)malignant lesions in human liver show
significant similarities, such as mutations of the wnt-pathway,
overexpression of TGFa, IGF-I and -II and other growth factors
(Miller et al, 1995; Grisham, 1997; Yamada et al, 1999; Yang et al,
2003). Rates of replication and death of GSTp
þ cells, and thus
overall cell turnover, are somewhat reduced in the single-cell stage,
but are significantly increased from the two-cell stage onwards
(Grasl-Kraupp et al, 1997, 2000). Thus, initiation causes a change
in the growth-regulatory network that becomes evident after the
first replication cylce of GSTp
þ cells. Treatment with tumour
promoters, such as the progestin cyproterone acetate (CPA), or
increased food intake further increases cell replication in
preneoplasia, which is analogous to human hepatocarcinogenesis
driven by anabolic steroids or overnutrition (Schulte-Hermann
et al, 1990; Grasl-Kraupp et al, 1994; Fiel et al, 1996; Nair et al,
2002). This enhanced sensitivity of liver preneoplasia towards the
various growth stimuli could result from an altered uptake,
production and/or processing of endogeneous growth regulatory
factors by the premalignant cell compartment.
In the present study, we asked whether the nuclear occurrence of
proTGFa ´ is involved (i) in the altered growth regulation of
(pre)malignant hepatocytes and (ii) in the enhanced sensitivity of
these cells towards induction of DNA replication by known growth
stimulators. Recently, preneoplastic rat liver cells have become
available for investigation in an ex vivo culture model (Lo ¨w-Baselli
et al, 2000b). We applied this model, in combination with studies
on human livers, and found that proTGFa-positive nuclei increased
in the course of hepatocarcinogenesis. The possible role of nuclear
proTGFa for the growth advantage of (pre)malignant cells is
discussed with regard to tumour-therapeutic strategies targeted at
TGFa/erbb-1 interactions on the cell surface.
MATERIALS AND METHODS
Human liver samples
Patients suffering from dysplastic liver nodules (n¼9), hepato-
cellular adenoma (n¼3), or HCC (n¼10) were resected;
chemotherapy had not been applied before surgery. Tissue samples
were immediately fixed in 10% buffered formaldehyde. Classifica-
tion of liver lesions and stage of disease followed published
guidelines (Edmondson and Steiner, 1954; Hermank et al, 1993;
International Working Party, 1995). For further details, see Table 1.
Informed consent was obtained from all patients.
Human hepatocyte and hepatoma cell lines
The human hepatoma cell lines HepG2 (ATCC-No HB-8065), Hep
2B2.1–7. (ATCC-No HB-8064), and WRL 68 (ATCC-No CL-48)
were obtained from the American Type Culture Collection
(Rockville, MD, USA). The cells were maintained in vitro at 371C
and 5% CO2 in Dulbecco’s minimum essential medium (DMEM)
supplemented with 5% foetal calf serum, 100Uml
 1 penicillin and
100mgml
 1 streptomycin (all obtained from Gibco, Life Techno-
logies Inc., Gaitherburg, MD, USA). Once per week cells were
passaged at a seed density of 1 10
6 cells per 25cm
2 plate.
Animals and treatment
Male SPF Wistar rats, about 3 weeks old, were obtained from the
Institut fu ¨r Versuchstierkunde und Genetik (Himberg, Austria).
Animals were kept under standardised conditions and were fed
powder diet (Altromin 1321N, Altromin, Lage, FRG). At 3 weeks
before treatment, animals were adapted to rhythmic feeding (from
0900 to 1400h). This procedure synchronises DNA synthesis in the
liver to a single peak per day (Grasl-Kraupp et al, 1994, 2000).
After adaptation, animals were treated with a single dose of NNM
(Sigma, St Louis, MO, USA; 250mg per 10ml phosphate-buffered
saline per kg body weight). Phenobarbital (PB) was admixed to the
powder diet and was fed to a subgroup of rats from day 4 to 17
months post-NNM. Concentrations of PB were adjusted every 14
days to provide a daily dose of 50mgkg
 1 body weight (Lo ¨w-
Baselli et al, 2000b). Animals were killed by decapitation under
CO2 asphyxation. For further details, see Grasl-Kraupp et al (1994,
2000) and Lo ¨w-Baselli et al (2000a). All experiments were
performed according to the ‘Austrian Guidelines for Animal Care
and Protection’, which meet the standards required by the
‘UKCCCR Guidelines for the Welfare of Animals in Experimental
Neoplasia’ (2nd edn.) (Workman et al, 1998).
Histology
Human and rat liver samples, fixed in 10% buffered formaldehyde,
were processed as described (Grasl-Kraupp et al, 1994, 2000;
Table 1 Age and sex of the patients, causative factors for the
development of disease, histopathological diagnoses and TNM classification
Age Sex Aetiology Liver changes Diagnosis
27 f Glycogenosis 1 S, glycogenosis HCA
33 f S HCA
46 f HCA
39 m S, H DN-LG
37 f S, H DN-LG
48 m F DN-LG
25 f U DN-LG
52 f U DN-HG
55 m HCV C DN-HG
61 m HCV C DN-HG
50 m HCV C DN-HG
77 m C DN-HG
63 f HCC/1, pT1, pN0, pM0
59 f HCC/1, pT2, pN0, pM0
67 m C HCC/2, pT2, pN0, pM0
64 m Ethanol C HCC/2, pT3, pN0, pM0
68 m HCC/2, pT3, pN0, pM0
59 f HCV C HCC/2, pT3, pNx, pM0
53 m Ethanol C HCC/2, pT4, pN0, pM0
63 m HCV HCC/2, pT4, pN0, pM0
58 m Ethanol C HCC/3, pT4, pNx, pM0
77 f HCC/3, pT4, pNx, pMx
m, male; f, female; HCV, hepatitis-C-virus infection; C, cirrhosis, F, fibrosis, H, hepatitis;
S, steatosis; U, unaltered liver parenchyma; HCA, hepatocellular adenoma; DN-LG,
low-grade dysplastic nodule; DN-HG, high-grade dysplastic nodule; HCC, hepato-
cellular carcinoma. HCC/1–3 refers to the histopathological grading of the HCCs
according to published criteria (Edmondson and Steiner, 1954). The TNM staging
(tumour/node/metastasis) of the disease followed the UICC guidelines (Hermank
et al, 1993).
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sLo ¨w-Baselli et al, 2000a); two serial sections, 1mm thick, were cut;
one of the sections was stained for GSTp (rat only) or Ki-67
(human only), the second one was stained for TGFa.
Immunostaining for TGFa, GSTp and Ki-67 The primary
antibodies used were rabbit polyclonal IgG against rat Yp-subunit
of GSTp (Biotrin International, Dublin, Eire); mouse monoclonal
IgG against recombinant mature TGFa encompassing amino acids
39–88 (clone 213-4.4, Oncogene Science, Uniondale, NY, USA);
mouse monoclonal IgG against a synthetic peptide encompassing
amino acids 144–160 of the C-terminus of proTGFa (Ab-3;
InnoGenex, San Ramon, CA, USA); mouse monoclonal antibody
against full-length recombinant Ki-67 protein (Dianova, Hamburg,
FRG).
For TGFa or Ki-67 staining, formaldehyde-fixed and de-waxed
tissue sections were placed in a glass Coplin jar filled with 0.01 M
sodium citrate buffer, pH 6.0. Slides were heated for periods of
2min at a maximal power setting (about 800W) and for 2 2min
at the submaximal power setting (600W). The citrate buffer
reached boiling point within 2min and the fluid level in the Coplin
jar was topped up with distilled water between heating periods to
prevent drying of the sections.
The following staining schedule was used: hydrogen peroxide to
block endogenous peroxidases (3%, 20min, room temperature);
incubation with 2.5% bovine serum albumin (BSA) in TBS
(0.05 M Tris, 0.3 M NaCl, pH 7.6; 30min, room temperature);
primary antibodies were diluted in 1% BSA-TBS (anti-Yp: 1:5000;
anti-TGFa: 1:50; anti-Ki-67:1:50) and applied overnight
at 41C; rinsing with TBS; secondary antibodies were diluted in
2.5% BSA-TBS (biotinylated goat-anti-rabbit IgG or biotinylated
rabbit-anti-mouse IgG; both 1:600, Dakopatts, Glostrup, Den-
mark) and were applied for 90min at room temperature; rinsing
with TBS was followed by incubation with streptavidin–horse-
radish peroxidase conjugates (1:300 in TBS, 45min, room
temperature; Dakopatts); diaminobenzidine (Sigma, St Louis,
MO, USA) was used for colour development. The specificity of
immunohistochemistry was confirmed by omitting the primary
antibodies.
Determination of DNA synthesis
Rat liver
3H-thymidine (6.7Cimmol
 1; NEN, Frankfurt, FRG)
was injected into the peritoneal cavity as a single dose of
0.2mCikg
 1 body weight at the daily peak of DNA synthesis
between 2000 and 2100h (see above). After 36h, animals were
killed. GSTp-stained sections were coated with a solution of 1%
gelatine (BioRad, Richmond, CA, USA) and 0.05% chromalaun
(Merck, Darmstadt, FRG) and were air-dried. After autoradio-
graphy, the percentage of hepatocyte nuclei in DNA synthesis was
determined for at least 1000 nuclei of unaltered cells in each liver
and in all nucleated cells within individual GSTp
þ foci (labelling
index (LI)). Since interindividual variations were small, LIs
obtained from different livers or foci of the same experimental
group were pooled.
Human liver In order to identify human hepatocyte nuclei in the
S-phase of the cell cycle, serial sections were stained for TGFa and
Ki-67 (see above). Individual Ki-67-positive nuclei were followed
in the consecutive TGFa-stained serial section by overlaying the
two images in two microscopes linked by a bridge for over-
projection (Zeiss, Germany).
Primary hepatocytes
Male SPF Wistar rats were obtained from the animal facilities of
the Medical University of Vienna at the age of 3–4 weeks and were
treated with a single dose of NNM (250mgkg
 1 body weight), as
described above. After 21 days, livers were perfused with
collagenase as described (Parzefall et al, 1989; Lo ¨w-Baselli et al,
2000b).
Treatment of primary hepatocyte cultures Cells were seeded and
kept under serum-free conditions, as described (Parzefall et al,
1989; Lo ¨w-Baselli et al, 2000b). Treatment commenced 4h after
plating (time point 0). A stock of 10mg(10ml)
 1 of 10mM acetic
acid of human recombinant mature TGFa (UBI, Lake Placid, NY,
USA) was prepared and was added to the medium for a final
concentration of 10ngml
 1. Tyrphostin A25 (synonym: tyrphostin
AG82; Calbiochem, La Jolla, CA, USA) was dissolved in
dimethylsulphoxide (DMSO) to obtain a stock of 10mgml
 1;1ml
of this stock was added per ml medium. Cyproterone acetate, a gift
from Schering AG (Berlin, FRG) was dissolved in DMSO. In all
experiments, the final concentration of CPA was 10mmol in 0.2%
solvent. Recombinant mature TGFb1 synthesised by CHO
transfectants was supplied gratuitously by Bristol-Myers Squibb
(Seattle, WA, USA). TGFb1 was dissolved as described (Oberham-
mer et al, 1992).
Double immunostaining of culture plates for GSTp and TGFa -
Cells in culture were fixed for 90min at room temperature with 4%
buffered formalin according to Lillie and were then kept in
distilled water at 41C until immunostaining. Then, the following
schedule was used: hydrogen peroxide to block endogenous
peroxidases (3%, 20min, room temperature); primary antibodies
were diluted in 2.5% BSA in TBS (0.05 M Tris, 0.3 M NaCl, pH 7.6)
(rabbit-anti-Yp 1:5000; mouse-anti-TGFa 1:50; mouse-anti-
proTGFa 1:50) and applied overnight at 41C; rinsing with TBS;
secondary antibodies were diluted in 2.5% BSA–TBS (biotinylated
goat-anti-mouse IgG or alkaline-phosphatase-labelled goat-anti-
rabbit; both 1:600; Dakopatts) and were used for 90min at room
temperature; rinsing with TBS was followed by incubation with
streptavidin (1:300 in TBS, 45min, room temperature; Dakopatts);
diaminobenzidine (Sigma), 5-bromo-4-chloro-3-indolylphosphate
and nitro blue tetrazolium chloride (Boehringer, Mannheim, FRG)
were used for colour development. Omission of the primary
antibodies served as control.
Determination of DNA replication in cultured hepatocytes Im-
munohistochemically stained plates were coated with 1% gelatine/
0.05% chromalaun, air-dried, dipped into photo-emulsion (Ilford
K5, Dreieich, FRG), and exposed for about 14h. The plates were
processed with a photographical developer and fixative, and were
finally dried at room temperature and mounted in Kayser’s
glycerine gelatine (Merck, Darmstadt, FRG). The LI was calculated
as percentage of labelled hepatocyte nuclei per total number of
hepatocyte nuclei counted.
Two-dimensional gel electrophoresis, immunoblotting and
identification of protein spots
Nuclei and cytoplasm (postnuclear supernatant) of human
hepatoma cells and of rat liver were separated according to the
method of Tata, applying 2.0 M sucrose for purification (Tata,
1974). This was followed by a nuclear matrix preparation, as has
been described in detail (Gerner et al, 1998).
The electrophoretically separated proteins were transferred
onto PVDF sheets; the filters were soaked in excess blocking
buffer ((3% BSA, Sigma, St Louis, MO, USA) in TBST buffer
(10mM Tris–HCl, pH 8, 150mM NaCl, 0.1% Tween 20)). The
mouse monoclonal antisera against amino acids 39–88 of mature
TGFa (Oncogene Science, Ab-1, clone 134A-2B3; 1:300) were
diluted in TBST buffer and were incubated overnight at 41C.
Thereafter, sheets were incubated for 1h at room temperature with
an alkaline phosphatase-conjugated anti-mouse IgG (Promega,
Madison, WI, USA) diluted 1:7000 in TBST buffer containing
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s0.25% BSA; 5-bromo-4-chloro-3-indolylphosphate and nitro blue
tetrazolium chloride (Boehringer, Mannheim, FRG) were used for
staining.
For mass spectrometry fingerprinting, Coomassie Blue-stained
proteins were directly cut out of preparative gels. Matrix-assisted
laser desorption ionisation-time-of-flight (maldi-tof) of tryptic
protein hydrolysates and protein identification were carried
out essentially as described (Fountoulakis and Langen, 1997;
Grasl-Kraupp et al, 2002). Proteins were considered identified by
means of mass spectrometry fingerprinting when at least 15% of
the whole sequence gave hits and when the molecular mass/pI
values were identical to the ones calculated or published in 2D
databases.
Statistics
If not stated otherwise, data of at least three animals per time point
and treatment group are given. Where indicated, the significance
of differences of means was calculated by Kruskal–Wallis test or
Wilcoxon test. For incidences, confidence intervals were calculated
for Po0.05.
RESULTS
The pro-peptide of TGFa is present in the nuclei of human
and rat hepatocytes and human hepatoma cell lines
In anti-TGFa-stained liver sections, immunoreaction was found
within the cytoplasm, cell membranes and, most prominent, the
nuclei of hepatocytes (Figure 1B, C and E). Likewise, the nuclei of
the hepatoma cell lines HepG2 (Figure 1F), WRL68 and Hep2B
(not shown) displayed a strong immunoreaction. Nuclear matrices,
prepared from human HepG2 cells (Figure 2A) and from rat liver
(Figure 2B), were separated by two-dimensional gel electrophoresis
and were subsequently subjected to anti-TGFa immunoblotting;
four spots around 17kDa and an isoelectric point of 7.5 appeared.
Spots 1–4 of HepG2 cells were subjected to maldi-tof analysis: spot
1 was verified to be the wild-type form of proTGFa; spot 2 was
recently found to be wild-type proTGFa as well (Grasl-Kraupp et al,
2002). Spots 3 and 4 could not yet be identified. Immunostaining
with antisera against the C-terminus of the pro-peptide also
confirmed the presence of proTGFa in hepatocyte nuclei (see
below). The mature form of TGFa at about 5.6kDa was not
detected.
Figure 1 Occurrence of nuclear proTGFa in human and rat hepatocarcinogenesis. (A–C) Rat liver 12 months post-NNM: serial sections of a
preneoplastic lesion stained for GSTp (A) and TGFa (B); (C) HCC with proTGFa-pos nuclei (C). (D) Preneoplastic GSTp
þ hepatocytes (violet) with
proTGFa-pos nucleus (brown) and incorporated
3H-thymidine (black spots) in primary culture; hepatocytes were isolated at day 21 post-NNM and cultured
for 48h;
3H-thymidine was added to the medium 24h before harvesting. (E) Human HCC and (F) human HepG2-hepatoma cells with proTGFa-pos nuclei.
Magnifications:  50 for (A), (B),  75 for (E);  25 for (C);  200 for (D, F).
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sOccurrence of DNA replication and nuclear proTGFa in the
different stages of human hepatocarcinogenesis
The percentage of both, replicating nuclei and proTGFa-pos nuclei,
was gradually increased from normal liver, to hepatocellular
adenoma, to dysplastic nodules, to HCC (Table 1, Figure 3). In
unaltered liver, replicating nuclei and proTGFa-pos nuclei
occurred at a similar frequency. Premalignant and malignant liver
lesions, however, revealed a much higher percentage of proTGFa-
pos nuclei when compared to nuclei in S-phase (Figure 1E and 3).
Staining for Ki-67 was used to identify hepatocyte nuclei in the S-
phase of the cell cycle (for details, see Materials and methods); five
HCC were studied: 77.379.2% of 343 Ki-67-positive hepatocyte
nuclei evaluated displayed proTGFa. A high co-incidence of DNA
synthesis and proTGFa was recently shown also for hepatocyte
nuclei in cirrhotic liver (Grasl-Kraupp et al, 2002). Taken together,
these findings indicate that a hepatocyte nucleus undergoing DNA
replication almost always contains proTGFa. Further expression of
proTGFa in nuclei not immediately undergoing DNA synthesis
occurs predominantly in premalignant and malignant hepatocytes.
Occurrence of DNA replication and nuclear proTGFa in the
different stages of rat hepatocarcinogenesis
Hepatocarcinogenesis was induced in rats by application of NNM.
This leads to the formation of single GSTp
þ cells and small
preneoplastic GSTp
þ lesions, followed by expansive growth of
some of the lesions. To enhance the formation of liver tumours,
rats were treated with the tumour promoter PB (Lo ¨w-Baselli et al,
2000b). Analogous to the findings in human liver, proTGFa-
positive nuclei occurred in (pre)malignant hepatocytes at a
significantly higher incidence than in unaltered hepatocytes
(Figures 1A–C and 3). This substantiates that the experimental
model fits the human situation.
Inherent growth advantage of cultured preneoplastic
GSTp
þ rat hepatocytes associated with nuclear proTGFa
To study the functional significance of nuclear proTGFa for
hepatocarcinogenesis, unaltered GSTp
  and preneoplastic GSTp
þ
cells were isolated from the livers by collagenase perfusion and
cultivated. Cell isolation was performed on day 21 post-NNM
treatment (no PB promotion). At this time point, there is the
maximal occurrence of GSTp
þ cell clones in the liver. Based on
stereological calculations of the size distribution in the third
dimension, only 23711% of the isolated GSTp
þ cells in culture
derive from single-cell clones and 77729% derive from small foci
(three cells on average), with an inherently elevated cell turnover
(DeGunst and Luebeck, 1998; Grasl-Kraupp et al, 2000).
Replicative DNA synthesis was generally high in the isolated
hepatocytes (Figure 4); this may be explained by the fact that the
livers still underwent regeneration, as observed in vivo (Grasl-
Kraupp et al, 2002). ProTGFa was present in the nuclei of about
10% of the hepatocytes in primary culture (Figure 4 and Table 2).
In any case, DNA replication occurred preferentially in proTGFa-
pos nuclei in both GSTp
  and GSTp
þ hepatocytes (Table 2). This
was also confirmed by immunostaining of parallel culture plates
with two different antisera: DNA was synthesised by 76.576.8% of
the nuclei being positive for amino acids 39–88 of proTGFa
(encompassing the mature form) and by 65.3719.2% of the nuclei
being positive for amino acids 144–160 of the C-terminus of the
pro-peptide. In both stains, DNA synthesis in negative nuclei was a
rare event (see also Table 2).
GSTp
þ cells showed an about three-fold higher frequency of
proTGFa-pos nuclei and DNA replication than GSTp
  cells
(Figure 4 and Table 2). Thus, the inherent growth advantage of
the cultured preneoplastic cell population appears to be highly
associated with the enhanced nuclear translocation of proTGFa.
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Figure 2 Detection of proTGFa in the nuclear fraction of human
HepG2-hepatoma cells and of rat liver. Nuclear matrix proteins of
hepatoma cells (A) and of an untreated male rat liver (B) were subjected
to two-dimensional immunoblotting. The gels covered a range of pI 3–8
and Mr 4–40kDa. (A) Spots 1–4 were analysed by maldi-tof: spot 1 was
identified as wild-type proTGFa; * indicates the amino-acid sequence
identified, which covers 19% of the total pro-peptide of TGFa.
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Figure 3 Increased cell replication and incidences of proTGFa-pos nuclei
in human and rat hepatocarcinogenesis. White columns represent the
percentage of nuclei in S-phase (LI%), dark columns the percentage of
proTGFa-pos nuclei. Humans: three hepatocellular adenomas, nine
dysplastic nodules, 10 heptocellular carcinomas and the surrounding liver
of the 22 cases were evaluated. At least 1000 hepatocyte nuclei (on
average 2055 nuclei) per liver or tumour were screened for Ki-67 and
proTGFa positivity. Rats: time interval between
3H-thymidine injection and
killing was 36h. The percentages of proTGFa-pos nuclei and LI were
determined at least in: 2000 nuclei of GSTp
  and 1221 nuclei of GSTp
þ
hepatocytes per liver (n¼13); 1381 nuclei per adenoma (n¼15); 1362
nuclei per carcinoma (n¼14). nl, normal liver; pr, preneoplastic GSTp
þ
lesion; ad, hepatocellular adenoma; dn, dysplastic nodule; ca, HCC.
Incidences are given; vertical lines give 95% confidence intervals: no
overlap indicates a statistically significant difference for Po0.05.
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sDifferent signal transduction pathways of TGFa gene
products in GSTp
  and GSTp
þ hepatocytes
We have confirmed recently that in our system mature TGFa acts
via erbb-1 in the cellular membrane of proTGFa-neg cells
according to classical concepts of growth signal transduction
(Grasl-Kraupp et al, 2002). Accordingly, in the present study,
addition of mature TGFa increased DNA synthesis almost
exclusively in the GSTp
  cells that do not express proTGFa. This
increase in DNA synthesis was blocked by the erbb-1-tyrosine
kinase inhibitor tyrphostin A25 (Figure 5). However, mature TGFa
exerted no significant effect on any cell with nuclear proTGFa,
which was most evident for the proTGFa-rich GSTp
þ population
(Figure 5). At present, it is unclear why TGFa exerted no effect on
the GSTp
þ cells with proTGFa-neg nuclei. The expression of yet
unidentified growth factors may confer autonomy from exoge-
neous growth stimuli to this subpopulation of premalignant cells.
Taken together, these findings suggest that two different TGFa-
mediated signal transduction pathways are operative in different
cell populations: the ‘classical’ erbb-1-mediated pathway of mature
TGFa becomes active mostly in the proTGFa-poor GSTp
 
hepatocytes, while the second one, triggered by nuclear proTGFa,
is effective in the proTGFa-rich preneoplastic GSTp
þ cells.
Transforming growth factor-b1 reduces DNA synthesis and
nuclear proTGFa in cultured GSTp
  and GSTp
þ
hepatocytes
DNA replication was suppressed by 1ng of TGFb1 and even more
by 3ng of TGFb1ml
 1 medium in GSTp
  and GSTp
þ cells
(Figure 6). DNA replication was inhibited at the most effective
concentration of the cytokine in about 66% of the GSTp
  cells, but
in at least 90% of the GSTp
þ cells. These data suggest that TGFb1
acts more strongly on GSTp
þ than on GSTp
  cells. Furthermore,
TGFb1 diminished the fraction of hepatocytes expressing nuclear
proTGFa and synthesising DNA (Figure 6 and Table 2). Appar-
ently, the suppression of DNA synthesis by TGFb1 in primary
hepatocytes involves downregulation of nuclear proTGFa. This
effect was evident for both, GSTp
  and GSTp
þ cells.
Table 2 DNA synthesis occurs preferentially in proTGFa-pos nuclei
CO CPA TGFb1 (10ng)
In GSTp
— In GSTp
+ In GSTp
— In GSTp
+ In GSTp
— In GSTp
+
%o fproTGFa-pos nuclei 10.372.9 29.079.9* 20.773.2** 46.177.2* 2.071.1** 10.171.9***
,**
%o fproTGFa-pos nuclei in S phase 76.576.8 62.177.8 81.774.3 75.175.8 41.1720.4 10.275.9**
%o fproTGFa-neg nuclei 89.772.9 71.079.9**** 79.373.2 53.977.2***
,**** 98.071.1***** 89.973.9****
,*****
%o fproTGFa-neg nuclei in S phase 4.571.3 6.974.9 9.673.6 12.575.7 1.071.0***** 0.670.4*****
3H-thymidine was added 24h before harvesting of cells. The percentage of nuclei in S phase and of proTGFa-pos nuclei were determined after 48h of culture. In each
experiment, 2000 nuclei of GSTp
— cells and 600 nuclei of GSTp
+ cells were evaluated. Means7s.d. are given from separate experiments with cultures from five rats. Statistics by
Wilcoxon’s test for GSTp
— cells vs GSTp
+ cells. ****Po0.05, ***Po0.01, *Po0.001; for Co vs treated group: *****Po0.05, **Po0.01.
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Figure 5 Mature TGFa increases the percentage of nuclei in S-phase
(LI%) preferentially in GSTp
  hepatocytes without nuclear proTGFa.
3H-
thymidine was added 24h before harvesting of cells. The percentages of
replicating and of proTGFa-pos nuclei were determined after 48h of
culture. For the number of experiments and cells scored, see Figure 4.
Hatched portions of the bars indicate LI of proTGFa-pos nuclei;
nonhatched portions of the bars indicate LI of proTGFa-neg nuclei; the
sum of the hatched and unhatched portion (total bar) indicates LI of all
nuclei; Co: DMSO-control; TGFa: mature TGFa; Tyr: Tyrphostin A25.
Statistics by Student’s t-test: (a) Po0.05.
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Figure 4 DNA synthesis (LI(%)) and % of proTGFa-pos nuclei in
cultured GSTp
  and GSTp
þ hepatocytes.
3H-thymidine was added 24h
before harvesting of cells. The % of proTGFa-pos nuclei was determined
after 48h of culture. Symbols: D or open columns, GSTp
  cells; ’ or dark
columns, GSTp
þ cells. In each of the experiments, 2000 nuclei of GSTp
 
cells and 600 nuclei of GSTp
þ cells were evaluated. Means7s.d. are given
from separate experiments with cultures from five rats. Statistics of LI(%) in
GSTp
  vs GSTp
þ cells over time-course by Kruskal–Wallis test: (a)
Po0.001. Statistics of LI(%) in GSTp
  cells vs GSTp
þ cells at the last time
point of evaluation by Wilcoxon’s test: (b) Po0.01. Statistics of % of
proTGFa-pos nuclei in GSTp
  vs GSTp
þ cells by Wilcoxon’s test: (c)
Po0.001.
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sThe hepatomitogen CPA induces DNA synthesis and
nuclear proTGFa in GSTp
  and GSTp
þ hepatocytes
Treatment with the hepatomitogen CPA doubled the LI in cultured
GSTp
  and GSTp
þ cells (Figure 7). Thus, every fifth GSTp
þ cell
was stimulated to DNA synthesis by CPA, while only every
tenth GSTp
  cell was recruited to the pool of replicating
hepatocytes. We asked whether nuclear proTGFa might be
involved in this enhanced growth stimulation of the preneoplastic
cell population. In fact, the CPA-induced increases in DNA
synthesis were closely paralleled by an equal elevation of
proTGFa-pos nuclei (Figure7 and Table 2). This may indicate that
the enhanced occurrence of nuclear proTGFa in liver preneoplasia
may commit the preneoplastic cells for preferential response
towards growth stimulation.
DISCUSSION
The present paper describes that the pro-form of TGFa occurs in
the nucleus of (pre)malignant rat and human hepatocytes, while
mature TGFa was not detected. The translocation of proTGFa to
the nucleus may contribute to the inherent growth advantage of
early and late stages of hepatocarcinogenesis. The present
observations extend recent findings on normal hepatocytes from
rat, mouse and humans, which revealed that the translocation of
proTGFa to the nucleus in G1 of the cell cycle is almost always
followed by replicative DNA synthesis (Grasl-Kraupp et al,
2002). Nuclear translocation of proTGFa is induced by various
hepatomitogenic stimuli, such as regenerative growth after
partial hepatectomy or intoxication with CCl4 and hyperplastic
growth induced by CPA in the intact animal. In culture, the
incidence of proTGFa-pos hepatocyte nuclei is elevated by
treatment with hepatomitogenic CPA, prostaglandins E2 and
F2a, and hepatocyte growth factor (Grasl-Kraupp et al, 2002;
Schausberger et al, 2003). Thus, a great variety of growth stimuli
all involve nuclear translocation of proTGFa. This peptide may
therefore serve as a kind of intracellular shortcut in mediating
autocrine growth stimulation of normal, premalignant and
malignant liver cells.
The possible interactions of proTGFa with the growth-regulatory
machinery in the nucleus of unaltered and (pre)neoplastic
hepatocytes are still unclear. Soluble or membrane-bound
precursors of TGFa are biologically active, suggesting that the
pro-form may attach to the binding site of erbb-1 as known for the
mature form (Ignotz et al, 1986). We found that proTGFa and
erbb-1 almost always co-localise within the nucleus of mouse
hepatocytes, as shown by confocal laser-scanning microscopy
(Schausberger et al, 2003). It is currently under investigation by
FRET technology whether the large TGFa precursor attaches to
erbb-1 and may be co-targeted to the nucleus as a receptor-bound
ligand. This may provide the clue for the function of this pro-
peptide for DNA synthesis, considering that erbb-1 may act as a
transcription factor for cyclin D1 (Lin et al, 2001). Our data also
suggest that the activity of proTGFa in the nucleus does not depend
on an erbb-1 receptor tyrosine kinase activity, since DNA
replication of proTGFa-pos nuclei was not affected by the tyrosine
kinase inhibitor tyrphostin (Figure 5).
The cell culture system used in the present study allows to
investigate the functional significance of nuclear proTGFa in
premalignant cells; cultured GSTp
þ hepatocytes showed signifi-
cantly higher basal rates of DNA replication than GSTp
 
hepatocytes. These characteristics closely reflect those described
for GSTp
þ cells in the intact liver in vivo. Thus, this defect in
growth regulation persists under culture conditions and therefore
appears to be independent of intercellular contacts within the
intact organ, and of cytokines, growth factors or hormones
circulating in the whole body. The present study shows that
considerably more GSTp
þ cells synthesise and transport proTGFa
to the nucleus than GSTp
  cells. The nuclear import of this pro-
peptide almost always is followed by DNA replication. The
enhanced probability of nuclear translocation of proTGFa may
therefore be essential for the intrinsic growth advantage of the
preneoplastic cell population. Compared to the current concepts of
signal transduction, nuclear proTGFa may not depend on intact
erbb-1 receptors on the cell surface. It circumvents the secretion
and possible loss of TGFa to the outside of the cell and may confer
autonomy and an inherent growth advantage, a pathway
preferentially used by the preneoplastic cell population.
In an untreated, healthy liver, almost all of the hepatocytes are in
the Go-phase of the cell cycle. In the present study, the incidence of
nuclei positive for proTGFa increased in the course of hepato-
carcinogenesis. Since proTGFa translocates to the nucleus in the
G1-phase of the cell cycle (Grasl-Kraupp et al, 2002), the elevated
presence of nuclear proTGFa in (pre)malignant hepatocytes may
be evidence for a G1-status of these cells. Several groups reported
that premalignant liver cells show an increased expression of
c-myc and cyclin D1, known inducers of the transition from G0 to
G1 of the cell cylce (Deguchi and Pitot, 1995; Ramljak et al, 2000).
On the other hand, the expression of the WAF1/CIP1 gene product,
p21 and the c-myc antagonist mad were decreased in hepatocarci-
nogenesis (Martens et al, 1996). Many growth-stimulating factors
exert their activity, provided that the target cell is in the G1-phase
of the cell cycle. Thus, the enhanced presence of nuclear proTGFa
in the (pre)neoplastic cell compartment appears to be involved in
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Figure 6 Transforming growth factor b1 reduces DNA synthesis and
proTGFa-pos nuclei in GSTp
  and GSTp
þ cells cultured for 48h.
3H-
thymidine was added 24h before harvesting of cells. Symbols: D, GSTp
 
cells, ’, GSTp
þ cells. Data are calculated as fold control; absolute values
are given in Table 1; number of experiments and cells scored see Figure 4.
Means7s.d. are given. Statistics by Kruskal–Wallis test for dose–response
effects within a cell population: (a) Po0.01; (b) Po0.05.
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Figure 7 Cyproterone acetate induces DNA synthesis and proTGFa-
pos nuclei in GSTp
  and GSTp
þ cells cultured for 48h.
3H-thymidine was
added 24h before harvesting of cells. Symbols: light columns, GSTp
  cells;
dark columns, GSTp
þ cells. For the number of experiments and cells
scored, see Figure 4. Means7s.d. are given. Statistics by Wilcoxon’s test for
Co vs CPA: (a) Po0.01; (b) Po0.05.
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facilitated response of liver (pre)neoplasia towards various growth
stimuli.
Transforming growth factor a and erbb-1 are upregulated in
malignancies of many different organs, including HCC. Novel
therapeutic approaches have been focusing on the possible benefit
of blocking TGFa-evoked signal transduction on the cell surface,
for example, by erbb-1 blockade (Levitzki and Gazit, 1995;
Mendelsohn, 1997). The present study shows that treatment with
mature TGFa stimulated DNA synthesis rather in proTGFa-neg
than in proTGFa-pos hepatocytes, which was abrogated by an erbb-
1-specific tyrosine kinase inhibitor. In GSTp
þ hepatocytes,
however, mature TGFa and tyrphostin exerted no significant
effect. Thus, the ‘classical’ signal transduction pathway of mature
TGFa via erbb-1 seems to be active in the unaltered cell
population, while the novel pathway seems to operate preferen-
tially in the (pre)malignant cell compartment. It is therefore
tempting to speculate that liver tumours may use alternative
pathways for growth stimulation by proTGFa. Then, they may be
resistant against therapeutic strategies targeted at TGFa/erbb-1
interactions on the cell surface.
In conclusion, the present work shows that the incidence of
nuclei expressing proTGFa is elevated in the course of rat
hepatocarcinogenesis, which may reflect and contribute to the
inherent growth advantage of (pre)neoplastic hepatocytes. Further
research is necessary to elucidate the mechanisms that regulate the
different intracellular routes of proTGFa and that may link nuclear
proTGFa to DNA replication.
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